“TOCILIZUMAB AS MONOCLONAL ANTIBODY THERAPY IN OVERCOMING ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19 PATIENTS”, JIMKI, vol. 9, no. 3, pp. 92–101, Apr. 2022, doi: 10.53366/jimki.v9i3.488.